UA114106C2 - Спосіб лікування прогестерон-залежного стану антипрогестином - Google Patents

Спосіб лікування прогестерон-залежного стану антипрогестином Download PDF

Info

Publication number
UA114106C2
UA114106C2 UAA201414106A UAA201414106A UA114106C2 UA 114106 C2 UA114106 C2 UA 114106C2 UA A201414106 A UAA201414106 A UA A201414106A UA A201414106 A UAA201414106 A UA A201414106A UA 114106 C2 UA114106 C2 UA 114106C2
Authority
UA
Ukraine
Prior art keywords
capsule
progesterone
amount
filling
oral
Prior art date
Application number
UAA201414106A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA114106(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA114106C2 publication Critical patent/UA114106C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA201414106A 2012-05-31 2013-05-30 Спосіб лікування прогестерон-залежного стану антипрогестином UA114106C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (1)

Publication Number Publication Date
UA114106C2 true UA114106C2 (xx) 2017-04-25

Family

ID=48614182

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201414106A UA114106C2 (xx) 2012-05-31 2013-05-30 Спосіб лікування прогестерон-залежного стану антипрогестином

Country Status (22)

Country Link
US (1) US10328022B2 (en:Method)
EP (1) EP2854763B1 (en:Method)
JP (1) JP6341910B2 (en:Method)
KR (1) KR102127348B1 (en:Method)
CN (1) CN104334158B (en:Method)
AU (1) AU2013267359C1 (en:Method)
BR (1) BR112014029131B1 (en:Method)
CA (1) CA2872644A1 (en:Method)
CL (1) CL2014003232A1 (en:Method)
CO (1) CO7141411A2 (en:Method)
CR (1) CR20140567A (en:Method)
EA (1) EA030444B1 (en:Method)
ES (1) ES2701400T3 (en:Method)
IL (1) IL235450B (en:Method)
IN (1) IN2014DN10548A (en:Method)
MX (2) MX363640B (en:Method)
NZ (1) NZ702467A (en:Method)
PH (1) PH12014502516A1 (en:Method)
SG (2) SG11201407397WA (en:Method)
UA (1) UA114106C2 (en:Method)
WO (1) WO2013181449A1 (en:Method)
ZA (1) ZA201408262B (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10064815B2 (en) * 2014-05-05 2018-09-04 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
EP3209282A4 (en) * 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2018251256B2 (en) * 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules
CN110678555B (zh) 2017-04-14 2023-10-13 比利时胶囊公司 制作普鲁兰的方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
ES2546336T3 (es) 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 19-norpregnadienodiona 17-alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida como agentes antiprogestacionales
IN191020B (en:Method) 2000-03-28 2003-09-13 Dabur Res Foundation
DK1328276T3 (da) 2000-10-18 2006-04-03 Schering Ag Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme
CN1954807A (zh) 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
CA2457526A1 (en) 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CN101163467B (zh) 2005-03-22 2012-07-18 雷普罗斯治疗公司 反式氯米芬的制药用途
JP2008536910A (ja) 2005-04-20 2008-09-11 ファイザー・リミテッド プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
EA200800974A1 (ru) * 2005-09-29 2008-10-30 Репрос Терапьютикс Инк. Композиции с улучшенной биодоступностью, содержащие стероидное производное и полигликолизированный глицерид
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
MY150763A (en) 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
JP5379121B2 (ja) * 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
WO2008129396A2 (en) 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
ES2467942T3 (es) 2007-09-20 2014-06-13 Lapidot Medical Import And Marketing Ltd Composiciones y medios para tratar leiomiomas uterinos, leiomioma, mioma, fibroides uterinos, endometriosis, adenomiosis y trastornos relacionados por mifepristona.
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2482914A1 (en) * 2009-09-29 2012-08-08 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
DE202011110355U1 (de) 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
CN104334158B (zh) 2018-08-10
AU2013267359B2 (en) 2016-05-26
CO7141411A2 (es) 2014-12-12
BR112014029131B1 (pt) 2021-03-09
CL2014003232A1 (es) 2015-03-13
MX2014014054A (es) 2015-02-12
KR20150014928A (ko) 2015-02-09
EP2854763B1 (en) 2018-09-26
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
PH12014502516B1 (en) 2015-01-12
US10328022B2 (en) 2019-06-25
CA2872644A1 (en) 2013-12-05
IL235450A0 (en) 2014-12-31
EA201492290A1 (ru) 2015-03-31
IN2014DN10548A (en:Method) 2015-08-21
MX363640B (es) 2019-03-28
AU2013267359C1 (en) 2016-09-29
CN104334158A (zh) 2015-02-04
US20150111862A1 (en) 2015-04-23
SG11201407397WA (en) 2014-12-30
ES2701400T3 (es) 2019-02-22
MX382986B (es) 2025-03-13
SG10201704858PA (en) 2017-07-28
AU2013267359A1 (en) 2014-11-20
EP2854763A1 (en) 2015-04-08
PH12014502516A1 (en) 2015-01-12
JP2015518052A (ja) 2015-06-25
CR20140567A (es) 2015-03-09
WO2013181449A1 (en) 2013-12-05
BR112014029131A2 (pt) 2018-05-29
ZA201408262B (en) 2015-12-23
IL235450B (en) 2020-02-27
EA030444B1 (ru) 2018-08-31
JP6341910B2 (ja) 2018-06-13
HK1206622A1 (en) 2016-01-15
MX2019003467A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
UA114106C2 (xx) Спосіб лікування прогестерон-залежного стану антипрогестином
ES2278925T3 (es) Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
CN103002873B (zh) 用于治疗子宫内膜异位症的释放芳香化酶抑制剂和孕激素的肠外剂型
ES2337129T3 (es) Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
TWI336623B (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
JP6796693B2 (ja) 抗プロゲスチンの膣内送達用の製剤と方法
ES2296943T3 (es) Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal.
ES2688821T3 (es) Métodos y composiciones para tratar afecciones dependientes de la progesterona
JP2001523639A (ja) プロゲストゲン−抗プロゲストゲンレジメン
HK40040572A (en) Formulations and methods for vaginal delivery of antiprogestins
HK1206622B (zh) 经阴道递送抗孕素的调配物和方法
HK1232125B (zh) 用於抗孕激素的阴道递送的制剂和方法